Latest Celgene Corp (CELGZ) Headlines Research
Post# of 2
Posted On: 03/12/2014 7:10:52 PM
Latest Celgene Corp (CELGZ) Headlines
Research and Markets: Nanotechnology Drug Delivery Market in the US 2012-2016 with Celgene Corp., Novartis AG and SkyePharma plc. Dominating
Business Wire - Wed Mar 12, 12:42PM CDT
Research and Markets (http://www.researchandmarkets.com/research/r75h94/nanotechnology) has announced the addition of the "Nanotechnology Drug Delivery Market in the US 2012-2016" report to their offering.
Nanotechnology Drug Delivery Market in the US 2012-2016 with Celgene Corp., Novartis AG and SkyePharma plc. Dominating
M2 - Wed Mar 12, 11:14AM CDT
Research and Markets (http://www.researchandmarkets.com/research/3r7bw6/nanotechnology) has announced the addition of the "Nanotechnology Drug Delivery Market in the US 2012-2016" report to their offering. The analysts forecast the Nanotechnology Drug Delivery market in the US to grow at a CAGR of 84.79 percent over the period 2012-2016. One of the key factors contributing to this market growth is the low R and D cost. The Nanotechnology Drug Delivery market in the US has also been witnessing the trend of emergence of personalized medicines. However, the increasing safety concerns could pose a challenge to the growth of this market. Key vendors dominating this space include Alkermes plc., Celgene Corp., Novartis AG and SkyePharma plc. Other vendors mentioned in the report are Merck and Co. Inc., Pfizer Inc., AlphaRx Inc., Amgen, Inc., Angiotech Pharmaceuticals, Inc., Biophan Technologies, Inc., Calando Pharmaceuticals, Inc., Cephalon, Inc., Cerulean Pharma, Inc, Copernicus Therapeutics, Inc., CritiTech, Inc., CytImmune Sciences, Inc., Elan Corporation, plc, Debiotech SA, F. Hoffmann-La Roche Ltd, Nano Interface Technology, Inc, Spherics, Inc., Spectrum Pharmaceuticals, Inc., SoluBest Ltd., Sigma-Tau Pharmaceuticals, Inc., PharmaNova Inc. Particle Sciences, Inc., Novavax, Inc., Nanotherapeutics, Inc., NanoSight Ltd., NanoCarrier Co. Ltd., NanoBioMagnetics, Inc., Nano Interface Technology, Inc, Merck Sharp and Dohme Corp., Kuecept Ltd., Izon Science Ltd. Commenting on the report, an analyst from the Healthcare team said: 'Over the years, the research activities in healthcare have changed significantly. There has been a paradigm shift away from blockbusters drugs to a more personalized medicine approach. The focus is being placed increasingly on formulating drugs based on the individual's unique genome and immune response. Personalized medicines have gained significant popularity because they enable the medical profession to provide customized treatment to patients. A customized treatment is based on the genetic as well as medical profile of a patient. Increasing knowledge about the molecular causes of diseases is increasing the demand for more targeted and effective nanotechnology-enabled drug delivery therapies.' For more information visit http://www.researchandmarkets.com/research/3r...technology About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
2014 Nanotechnology in Drug Delivery Global Strategic Business Report - Liposomes Leading the Way
M2 - Tue Mar 11, 6:28AM CDT
Research and Markets (http://www.researchandmarkets.com/research/6brvm7/nanotechnology_in) has announced the addition of the "Nanotechnology in Drug Delivery - Global Strategic Business Report" report to their offering. This report analyzes the worldwide markets for Nanotechnology in Drug Delivery in US$ Million. The Global Market is further analyzed by the following Drug Delivery Technologies: Nanocrystals, and Nanocarriers. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, Latin America, and Rest of World. Annual estimates and forecasts are provided for the period 2009 through 2018. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based on public domain information including company URLs. Key Topics Covered I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS II. EXECUTIVE SUMMARY 1. OUTLOOK 2. INDUSTRY OVERVIEW 3. TRENDS & ISSUES - Tough Market Conditions Drive Interest in Nanotechnology-Based Drug Delivery - Unmet Needs to Surge Interest in Nanotechnology- based Drug Delivery - Narrowing Drug Pipelines and Threat from Generics Raise Interest in Nanotechnology - Size - A Critical Factor in Improving Targeting Capability - Shape of Drug Carriers More Important than Size - A New Revelation - Existing Nanotechnology Drugs are Simple - Creation of New Therapeutics - The Next Avenue for Nanotechnology - Consumer Pull to Benefit Nanotechnology Based Drugs - Oral Therapies to Revel from Advances in Nanotechnology - Increasing Funding for Nanotechnology Based Therapeutics Development - Convergence of Enabling Technologies - A New Phase in Drug Delivery - Cloudy Future Threatens Advanced Drug Delivery Technologies with Premature Demise - Increasing Environmental and Health Concerns - A Critical Challenge to Technological Advancement - Limited Success and Scaling Up Issues Pose a Major Hurdle to Further Advancement - Financial and Economic Challenges Hurt Developmental Efforts - Higher Concentration of Research in Academia limits Commercialization - Collaborations Assume Importance - Nano Drug Delivery to Drive Tremendous Industry Activity Going Ahead - Challenges to Leveraging Technological Advancements for Boosting Drug Delivery Efficiency - Nanomedicine Regulation - the Approach and the Issues Associated - Regulations in Nanotechnology - Still Significant Room Exists for Improvement 4. NANOTECHNOLOGY-BASED DRUG DELIVERY APPLICATIONS 5. PRODUCT OVERVIEW 6. RECENT INDUSTRY ACTIVITY 7. FOCUS ON SELECT PLAYERS 8. GLOBAL MARKET PERSPECTIVE III. MARKET 1. THE UNITED STATES 2. CANADA 3. JAPAN 4. EUROPE 5. ASIA-PACIFIC 6. LATIN AMERICA 7. REST OF WORLD IV. COMPETITIVE LANDSCAPE Reasons To Buy The report profiles 60 companies including many key and niche players such as: - Access Pharmaceuticals - Alkermes - Aquanova - Camurus - Capsulution - Celgene - Ceramisphere - Crititech - EnColl - Enzon Pharmaceuticals - Flamel Technologies - Lena Nanoceutics - NanoBio? - NanoCarrier - Nano Interface Technology - pSivida For more information visit http://www.researchandmarkets.com/research/6b...hnology_in About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Global Orphan Drugs Market 2014-2018: Novartis, F. Hoffmann-La Roche, Celgene, Pfizer & Sanofi Dominate the Market
M2 - Fri Mar 07, 8:29AM CST
Research and Markets (http://www.researchandmarkets.com/research/73j57p/global_orphan) has announced the addition of the "Global Orphan Drugs Market 2014-2018" report to their offering. The Global Orphan Drugs market to grow at a CAGR of 5.67 percent over the period 2013-2018. The report states that one of the main challenges is the high cost of drug development. The rise in the cost of drug development often tends to discourage pharmaceutical innovators from developing orphan drugs. There has been increase in awareness about the potential benefits of orphan drugs among patients, surgeons, and hospitals. Public awareness about the use of orphan drugs is rapidly growing as a result of increasing social and public exposure and more advocacy groups and awareness campaigns. For instance, in 2010, the US FDA created the Rare Disease Program within the Office of New Drugs with the specific focus of developing the policies and procedures for the review of new drug applications for orphan drug products and to ensure access to appropriate training for US FDA reviewers. Similarly in 2012, the US FDA hosted the first ever US FDA Rare Disease Patient Advocacy Day to enhance the rare disease patient advocacy community's awareness of the US FDA's roles and responsibilities in the development of products for rare diseases. Thus, with the increasing awareness of orphan drugs, the market is expected to witness positive growth in the near future. According to the report, one of the main drivers in this market is the shorter development timelines. The clinical trials of orphan drugs for rare diseases involve fewer patients, which contributes to a shorter development process. The report covers the Americas, and the EMEA and APAC regions; it also covers the Global Orphan Drugs market landscape and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market. Key vendors dominating this space are: - Novartis AG - F. Hoffmann-La Roche Ltd. - Celgene Corp. - Pfizer Inc. - Sanofi S.A. For more information visit http://www.researchandmarkets.com/research/73...bal_orphan
Critical Alerts For Priceline.com, Celgene, CBS, Chipotle Mexican Grill, and AngloGold Ashanti Released By InvestorsObserver
PR Newswire - Thu Mar 06, 8:31AM CST
InvestorsObserver issues critical PriceWatch Alerts for PCLN, CELG, CBS, CMG, and AU.
Concise Analysis of the International Bispecific Antibody Therapeutics Market
M2 - Tue Mar 04, 6:18AM CST
Research and Markets (http://www.researchandmarkets.com/research/c63zqb/bispecific) has announced the addition of the "Concise Analysis of the International Bispecific Antibody Therapeutics Market" report to their offering. Antibody based therapeutics are the fastest growing segment of the drugs and biologics market. There are 30 approved antibody based therapeutics available in the US and European markets since the launch of first anti-CD3 antibody, Orthoclone Okt3, in 1986. A bispecific antibody is a second generation immunotherapy, an upgraded version of monoclonal antibody improved in structure and functionality. The conjugated artificial antibodies are formed by physically putting together two monoclonal antibodies (or parts of) which have different binding specificities. This results in a combination antibody that has simultaneous functional binding affinities to two or three different epitopes. The combination may have additive and sometimes even a synergistic effect in combating a disease. With the EMA approval for Removab in 2009, a great deal of interest has been generated in the bispecific antibody market. The pipeline is rich and diverse, with drugs being developed for both oncological and non-oncological indications. The industry has drugs in phase I and phase II of clinical trials but currently lacks drugs in phase III. The Bispecific Antibody Therapeutics Market, 2013-2023 report extensively studies the current and upcoming market of the bispecific antibodies for therapeutic use. This new class of antibody based therapeutics are likely to help target and combat multifactorial diseases through their potential to bind two antigens simultaneously. Key Topics Covered: 1. EXECUTIVE SUMMARY 2. INTRODUCTION 3. MARKET OVERVIEW AND PIPELINE OF BISPECIFIC ANTIBODIES 4. CURRENT MARKET AND FORECAST 5. TECHNOLOGY PLATFORMS 6. PROFILES OF LEADING COMPANIES 7. SWOT ANALYSIS 8. CONCLUSIONS 9. LIST OF COMPANIES AND ORGANISATIONS 10. TABLES Companies Mentioned: - Abbvie - Ablynx - BMS - Boehringer Ingelheim - Celgene - Chiome Bioscience - Chromacon - Chugai - Covagen - Dow Pharma - Dutalys - EMD Serono - Eli Lilly - Emergent - Epigen Biotech - Fabion Pharmaceuticals - GSK - Imclone Systems - Mitsubishi Tanabe - Molecular Partners AG - Novartis - Novimmune - Numab - OcellO - Oncomed - OtSuka Pharma - Paktis Antibody Services GmbH - Pfizer - Synimmune - Tanabe Research Labs - Trion - UCB-Celltech - X-Body Biosciences - Xencor - Zymeworks - Zymogenetics - Zyngenia For more information visit http://www.researchandmarkets.com/research/c63zqb/bispecific
Concise Analysis of the Future Prospects of Global Personalized Medicine Market
M2 - Tue Mar 04, 5:49AM CST
Research and Markets (http://www.researchandmarkets.com/research/zpctsr/future_prospects) has announced the addition of the "Concise Analysis of the Future Prospects of Global Personalized Medicine Market" report to their offering. Over the years, the Global Personalized Medicine market has been witnessing the emergence of various tools and technologies from the reputed vendors. For instance, AssureRx Health Inc. launched GeneSightRx ADHD in May 2012, a personalized medicine test for the growing number of children and adults diagnosed with ADHD. Moreover, Bristol-Myers Squibb Co. collaborated with MMRF in December 2012 for advanced personalized medicine for multiple Myeloma. Further, Alacris Theranostics GmbH entered into an agreement with GlaxoSmithKline plc in November 2012 to use ModCell system for early stage cancer research. Further, AltheaDx Inc. launched FLT3 Mutation Assay in October 2012. Agendia N.V. launched ColoPrint microarray-based 18-gene expression signature in June 2012 for predicting the risk of distant recurrence for stage II colon cancer patients. The European Medicines Agency approved Zelboraf, manufactured by F. Hoffmann-La Roche Ltd., in December 2011. Key Topics Covered: 1. Executive Summary 2. List of Abbreviations 3. Introduction 4. Market Research Methodology 5. Scope of the Report 6. Market Landscape 7. Geographical Segmentation 8. Key Leading Countries 9. Vendor Landscape 10. Buying Criteria 11. Market Growth Drivers 12. Drivers and their Impact 13. Market Challenges 14. Impact of Drivers and Challenges 15. Market Trends 16. Key Vendor Analysis 17. Other Reports in this Series Companies Mentioned: - Abbott Laboratories - Boehringer Ingelheim GmbH - Bristol-Myers Squibb Co. - Celgene Corp. - Daiichi Sankyo Co. Ltd. - Danaher Corp. - Eli Lilly and Co. - Evotec AG - F. Hoffmann-La Roche Ltd. - GE Healthcare Ltd. - Genelex Corp. - GlaxoSmithKline plc - Hologic Inc. - Johnson & Johnson - Laboratory Corporation of America Holdings - Life Technologies Corp. - Merck KGaA - Mitsubishi Tanabe Pharma Corp. - Myriad Genetics Inc. - Novartis AG - Novartis AG - PerkinElmer Inc. - Pfizer Inc. - Pfizer Inc. - Quest Diagnostics Inc. - Sanofi S.A. - Sanofi S.A. - Siemens Healthcare - Sigma-Aldrich Corp. - Takeda Pharmaceutical Co. Ltd. - Teva Pharmaceutical Industries Ltd. - Thermo Fisher Scientific Inc. - Transgenomic Inc. For more information visit http://www.researchandmarkets.com/research/zp..._prospects
Global Cell Therapy Market & Pipeline Insight Research Report
M2 - Tue Mar 04, 3:02AM CST
Research and Markets (http://www.researchandmarkets.com/research/5kmmgq/global_cell) has announced the addition of the "Global Cell Therapy Market & Pipeline Insight" report to their offering. Research in cell therapy is transforming the future of medicine. As the life of a human being begins as a cell, these cells undergo a highly complex set of events and finally those few stems become capable of self-renewal and differentiation and develop into the specialized cells in the body. Cell therapy research also offers significant potential for restructuring the method of medical practice. Over the past 3-5 years, a more complex therapeutic modality has been is emerging as cell therapies which have been developed to treat diseases which are not amenable to treatment with more classical pharmaceutical or biopharmaceutical products. This market offers the promise of successfully regenerating damaged tissues and organs in the body by replacing the damaged tissue and/or by stimulating the body's own repair mechanisms to heal previously irreparable tissues. With their rising popularity, these therapies are becoming more cost effective and efficient. The global market for cell therapy was valued at close to USD 2.5 Billion in 2012. With continuous advances and developments in this field of medicine, the global cell therapy market is expected to grow at a high rate of 20-22% to reach approximately USD 8 Billion by 2018. Several products and technologies of cell-based therapies are in the R&D pipeline are expected to enter the market during the forecast period, thus resulting in an increased growth rate. It is most likely that the new improved technologies would revolutionize the area of bio-pharma and personalized medicine. Development of sophisticated automation devices for cell expansion and culture process for use in the treatment is one of the emerging trends of ACT market. With the cell-based therapies growing by leaps and bounds, it is expected that the future years would witness significant advancements in technology in the cell therapy market. Increasing incidence of diseases along with lack of adequate effective treatment for these diseases is most likely to drive the cell therapy technology in developed and developing nations. Among the emerging trends of the global market, the most prominent one is the development of sophisticated automation devices for cell expansion and culture process which could be used in the treatment of life threatening diseases. Global Cell Therapy Market & Pipeline Insight Report Highlights & Findings: - Introduction to Cell therapy - Global Cell Therapy Market Overview - Global Cell Therapy Market Dynamics - Cell Therapy Pipeline by Phase, Country & Target Indications - Cell Therapy Drugs in Pipeline: More Than 200 - Highest Number of Drugs in Preclinical Stage: 73 - Number of Drugs in Phase I/II Stage: 35 - Key Market: US - Majority Cell therapies For Cancer Treatment Companies Mentioned - Advanced Cell Technology - Amgen - California Stem Cell - Celgene Corporation - Cytomedix - Fibrocell Science - Genzyme - NeoStem - Novartis - Stemedica Cell Technologies For more information visit http://www.researchandmarkets.com/research/5k...lobal_cell About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Abide Therapeutics Announces Strategic Drug Discovery Collaboration with Celgene Corporation to Advance Treatment Paradigm for Patients with Immune Disorders
PR Newswire - Fri Feb 28, 7:00AM CST
Abide Therapeutics today announced it has entered into a strategic collaboration with Celgene Corporation to discover and develop new drugs in inflammation and immunology. Abide has pioneered innovative technologies to selectively target serine hydrolases, one of the largest enzyme families involved in regulating human physiology.
Epizyme Announces 2013 Operating and Financial Results and Provides 2014 Guidance
PR Newswire - Thu Feb 27, 3:00PM CST
Epizyme, Inc. (NASDAQ: EPZM), a clinical stage biopharmaceutical company creating innovative personalized therapeutics for patients with genetically defined cancers, today announced 2013 operating and financial results and provided 2014 guidance.
Cystic Fibrosis Partnering 2009-2014 Research Report
M2 - Thu Feb 27, 3:45AM CST
Research and Markets (http://www.researchandmarkets.com/research/b4dg6p/cystic_fibrosis) has announced the addition of the "Cystic Fibrosis Partnering 2009-2014" report to their offering. Cystic Fibrosis Partnering 2009-2014 provides understanding and access to the cystic fibrosis partnering deals and agreements entered into by the worlds leading healthcare companies. The report provides an analysis of cystic fibrosis partnering deals. The majority of deals are discovery or development stage whereby the licensee obtains a right or an option right to license the licensors cystic fibrosis technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes. Understanding the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered - contract documents provide this insight where press releases do not. This data driven report contains over 50 links to online copies of actual liver disease deals and contract documents as submitted to the Securities Exchange Commission by companies and their partners, where available. Contract documents provide the answers to numerous questions about a prospective partner's flexibility on a wide range of important issues, many of which will have a significant impact on each party's ability to derive value from the deal. The initial chapters of this report provide an orientation of cystic fibrosis partnering trends. In Cystic Fibrosis Partnering 2009-2014, the available deals are listed by: - Headline value - Upfront payment value - Royalty rate value - Company A-Z - Industry sector - Stage of development at signing - Deal component type - Technology type Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand. Key Topics Covered: Executive Summary Introduction Trends in cystic fibrosis partnering Leading cystic fibrosis deals Dealmaking directory Partnering resource center Appendices Table of figures Companies Mentioned Abbott AstraZeneca Baxter International Celgene CSL Daiichi Sankyo Eisai Endo Pharmaceuticals Forest Laboratories Galderma Hospira Johnson & Johnson Kyowa Hakko Kirin Lundbeck Menarini Novartis Novo Nordisk Otsuka Pfizer Purdue Roche Sanofi Takeda Valeant Warner Chilcott Watson For more information visit http://www.researchandmarkets.com/research/b4...c_fibrosis About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Global Psoriasis Drug Forecast and Market Analysis to 2022 - Sales by region
M2 - Thu Feb 27, 2:55AM CST
Research and Markets (http://www.researchandmarkets.com/research/bkkwwm/pharmapoint) has announced the addition of the "PharmaPoint: Psoriasis - Global Drug Forecast and Market Analysis to 2022" report to their offering. 2012 PsO drug sales to be $5.6 billion across the nine major markets (9MM) covered in this report: US, France, Germany, Italy, Spain, UK, Japan, China, and India. By forecast end in 2022, sales will increase to over $7.62 billion at a Compound Annual Growth Rate (CAGR) of 3.1%, which includes seven pipeline therapies and the launch of biosimilars. This growth will be driven by: - The launch of novel PsO products, such as Eli Lilly's ixekizumab, Amgen's brodalumab, Novartis' secukinumab, Merck's MK-3222, Pfizer's Xeljanz (tofacitinib), Celgene's apremilast, and Biocon's Alzumab (itolizumab) - The uptake of biosimilars for the currently marketed biologics: etanercept, adalimumab, infliximab, and ustekinumab - Increased access to PsO biologics in China and India Despite these drivers, the PsO market will be crowded, yet comprised of diversified therapies. Individual drugs will struggle to gain a foothold as they distinguish themselves from each other. Unmet Needs in Psoriasis While dermatologists agree that the current biologics have revolutionized the PsO landscape, there is a dire need for therapies that can provide long-lasting effects, without side effects or an increased risk of comorbidities. The current pipeline includes at least four novel therapies that have exceptionally high clinical efficacy and good safety profiles, and these include: Novartis' secukinumab, Amgen's brodalumab, Merck's MK-3222, and Eli Lilly's ixekizumab. The dosing schedule for these therapies is quite convenient, as some of them are dosed once monthly and four times a year on average. Interestingly, of the seven pipeline products, three are me-too biologics, each of which targets the cytokine interleukin-17 (IL-17). However, we expect Novartis' inhibitor to be the first of this group to launch in 2014. Key Topics Covered: 1 Tables & Figures 2 Introduction 3 Disease Overview 4 Epidemiology 5 Disease Management 6 Competitive Assessment 7 Opportunity and Unmet Need 8 Pipeline Assessment 9 Current and Future Players 10 Market Outlook 11 Appendix Companies Mentioned - Amgen - AbbVie (Abbott) - Johnson & Johnson - Novartis - Pfizer - Eli Lilly - Merck - LEO Pharma - Celgene For more information visit http://www.researchandmarkets.com/research/bk...harmapoint
Chicago Investment Firm Assumes $27 Million Risk to Help Nuvilex Unseat Celgene and Eli Lilly
Marketwire - Mon Feb 24, 8:04AM CST
Lincoln Park Capital (LPC) purchased 8 million restricted shares of Nuvilex, Inc. (OTCQB: NVLX) in exchange for an initial $2 million out of what can be viewed as a $27 million "pot of money" to advance the company's late-phase pancreatic cancer clinical trials. Notice we said restricted shares, that's right, LPC has put a great deal of its money on the line with a number of built in protections for Nuvilex. But, is this investment really a risk? It appears the Chicago-based firm knows exactly what the future could hold for Nuvilex, and they're comfortable with paying a premium price to become a long-term investor right along with many others who believe in the small biotechnology firm.
US Orphan Drug Market Outlook 2018 Research Report
M2 - Mon Feb 24, 3:25AM CST
Research and Markets (http://www.researchandmarkets.com/research/nhk3cb/us_orphan_drug) has announced the addition of the "US Orphan Drug Market Outlook 2018" report to their offering. In the largest market for orphan drugs, USA, there was a shortage of adequate therapies for treating many rare diseases. These therapies were not developed as companies did not expect these drugs to be highly profitable. Hence there was a lack of interest and thus investment on the part of pharma companies in the USA. Therefore, the FDA introduced incentives for developing such drugs. This step taken by the FDA was successful in creating a thriving market for orphan drugs. It was in the USA first that a special law exclusively for governing orphan drugs was framed in the form of the Orphan Drug Act of 1983. This led to an increase in the popularity of orphan drugs. The FDA also has been continuously increasing its efforts to support this market by providing significant financial and non-financial incentives to the pharmaceutical companies to attract them. This has been one of the major drivers of growth for the US orphan drugs market. The orphan drugs enjoy significant competitive advantages in the market owing to the market exclusivity period after the drug has been authorized. Through this clause, the manufacturer of orphan drugs is given a monopoly status in the market because according to the law, no other company is allowed to market the orphan drugs during the exclusivity period. Additionally, this monopolistic power is further strengthened with the fact that no other alternative health technology exists for many orphan drugs. A scenario where orphan drugs would be denied coverage is highly difficult to visualize. However it is most likely that the payer scrutiny would increase with new products entering the market and budgets contracting in a weakening economic environment. The plans would be based on costs and would also include payer resources, philosophies, and available benefit design options, as all these factors could affect patient access. A deep and clear understanding of the clinical and economic value of the drugs will play an increasingly important role in decision-making. US Orphan Drug Market Outlook 2018 gives a comprehensive insight on following developments related to US orphan drug market: - US Orphan Drug Market Overview - Orphan Drug Designation Criteria - Market Specific Reimbursement Policy & Regulatory Framework - US Orphan Drug Pipeline by Phase, Indication & Originator - Marketed Orphan drug List by Indication & Brand Name - Key Issue to be Resolved - Competitive Landscape Key Topics Covered: Introduction to Orphan Drugs Why Shift from Non-Orphan to Orphan Drugs? US Orphan Drug Market Outlook US Orphan Drug Regulatory Framework US Orphan Drug Pipeline Insight by Phase & Indication Marketed Orphan Drugs in US: Brand Name & Indication Key Issue to be Resolved Competitive Landscape List of Tables List of Figure Companies Mentioned - Alexion - Biogen Idec - Bristol Myers Squibb - Celgene - Eli Lilly (Genzyme Corporation) - Glaxosmithkline - Merck - Novartis Pharmaceuticals - Pfizer - Rare Disease Therapeutics - Roche (Genentech) - Sanofi For more information visit http://www.researchandmarkets.com/research/nh...rphan_drug About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Move Over Celgene Here Comes Nuvilex and $27 Million to Advance Its Pancreatic Cancer Clinical Trials
Marketwire - Fri Feb 21, 8:00AM CST
Nuvilex, Inc. (OTCQB: NVLX) just became relevant in the biotech industry. The company can now move forward with its clinical trials for the treatment of advanced inoperable pancreatic cancer after Nuvilex landed a $27 million funding deal that could change the sector for years to come. Funding is always the biggest hurdle for any small biotechnology or pharmaceutical firm, and its why larger firms with competing treatments can often sit back without worry of new competition.
Bispecific Antibodies: Clinical Trial Tracker
M2 - Fri Feb 21, 4:31AM CST
Research and Markets (http://www.researchandmarkets.com/research/kmc65d/bispecific) has announced the addition of the "Bispecific Antibodies: Clinical Trial Tracker" report to their offering. Bispecific antibodies (bsAbs) are artificial antibodies created by joining together two monoclonal antibodies (or parts) that target different epitopes. The resulting antibody has binding affinities for two or three different epitopes concurrently. Various technology platforms have been used for bsAbs production over the years. These platforms are based on the concepts of chemical crosslinking, hybrid hybridomas, with the latest being recombinant techniques. Different binding sites can be exploited to produce bispecific systems with different mechanisms, such as the T cell engager system. As of now, only one bsAb, Removab, approved for malignant ascites is available in the market. The focus of the pipeline drugs is on oncology as well as on non-oncological indications such as rheumatoid arthritis and other inflammatory diseases. The primary objective of this report is to capture details on the various clinical and preclinical trials which are currently underway in the field of Antibody Drug Conjugates. A number of such trials which are taking place for a variety of indications across multiple geographies have been identified. The information has also been presented in the form a dashboard to provide a high level quick overview of the ongoing activity in this space. In addition to the clinical trial details, the report also provides the following: Detailed forecasts of the bispecific antibody market over the course of next ten years. Owing to the niche nature of this market, we have presented three scenarios to add robustness to our market forecast. The conservative, base and optimistic scenarios represent three different tracks of industry evolution. Industry SWOT analysis summarising the challenges as well as opportunities in the market for different stakeholders Key Topics Covered: I. Introduction and Pipeline Details Section 1: Market Overview Section 2: Dashboard: Pipeline Analysis Section 3: Molecules in Clinical Development: Trial Details Section 4: Molecules in Preclinical Development: Trial Details Section 5: Inclusion / Exclusion Criteria II Market Forecast, 2013 - 2023 Section 6: Market Forecast: Assumptions Section 7: Market Forecast: Details Section 8: Comparative Forecast Scenarios III. Industry Analysis Section 9: Industry SWOT Analysis List of Figures List of Tables Companies Mentioned - AbbVie - Baliopharm - Celgene - Dutalys - Eddingpharm - Fabion Pharmaceuticals - Ganymed Pharmaceuticals - Ho Research Consortium - ImClone System - Janssen Biotech - Krankenhaus Nordwest - MacroGenics - Nantes University Hospital - OncoMed Pharmaceuticals - Paktis Antibody Services GmbH - Radboud University - Sanofi - Technische Universit?t M?nchen - University Hospital Tuebingen - Xencor - Zymeworks and many more... For more information visit http://www.researchandmarkets.com/research/kmc65d/bispecific About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Worldwide Nanomedicine Market Report 2013-2019: Neurology, Cardiovascular, Anti-inflammatory, Anti-infective & Oncology Applications
M2 - Wed Feb 19, 9:05AM CST
Research and Markets (http://www.researchandmarkets.com/research/4bpxtn/nanomedicine) has announced the addition of the "Nanomedicine Market - Global Industry Analysis, Size, Share,Growth, Trends and Forecast, 2013 - 2019" report to their offering. This report includes market estimations for the nanomedicine market for the forecast period 2013 - 2019. The market size is represented in terms of USD billion and the market estimates and forecasts are calculated, considering 2012 as the base year. Moreover, market trends and recent developments have been kept into account while forecasting market growth and revenue for the period 2013 - 2019. The overall nanomedicine market is segmented on the basis of application and geography and the market estimations for each of these segments, in terms of USD billion, is provided in this report. The nanomedicine market, by applications is segmented into neurological, cardiovascular, oncology, anti-inflammatory, anti-infective and other markets. The nanomedicine market is also estimated and analyzed on the basis of geographic regions such as North America, Europe, Asia-Pacific and rest of the world. The global trends such as drivers, restraints and opportunities of the global nanomedicine market is detailed in the market overview chapter of this report., with a view on impact of these factors on market growth along the course of the forecast period. The chapter on competitive landscape consists of heat map analysis of the key players operating in the global nanomedicine market. Some of the key players of this market include GE Healthcare, Mallinckrodt plc, Nanosphere Inc., Pfizer Inc., Merck & Co Inc., Celgene Corporation, CombiMatrix Corporation, Abbott Laboratories and others. The role of these market players in the global nanomedicine market is analyzed by profiling them on the basis of attributes such as company overview, financial overview, product portfolio, business strategies, and recent developments. The global nanomedicine market is categorized into the following segments: - Neurology - Cardiovascular - Anti-Inflammatory - Anti-Infectives - Oncology - Others Key Topics Covered: Chapter 1 Preface Chapter 2 Executive Summary Chapter 3 Global Nanomedicine Market Overview Chapter 4 Global Nanomedicine Market, by Applications Chapter 5 Global Nanomedicine Market, by Geography Chapter 6 Recommendations Chapter 7 Company Profiles - Abbott Laboratories - Celgene Corporation - CombiMatrix Corporation - GE Healthcare - Johnson & Johnson - Mallinckrodt plc. - Merck & Company Inc. - Nanosphere, Inc. - Pfizer Inc. - Sigma-Tau Pharmaceuticals Inc. - Teva Pharmaceutical Industries Ltd. - UCB SA For more information visit http://www.researchandmarkets.com/research/4b...nomedicine
Cogent Reports(TM): Genentech Regains Its Dominance in Image Among Oncologists
Business Wire - Wed Feb 19, 9:00AM CST
Genentech has made notable gains as the top oncology franchise among oncologists over the past year, as evidenced by significantly higher scores across all key performance drivers, especially research and development (R&D) and developing beneficial products. Celgene and Amgen also show gains among oncologists, while Novartis remains the leader among hematologists. This and other findings can be found in the Cogent Reports Oncology Image Study from Market Strategies International.
Nuvilex's Pancreatic Cancer Treatment Readies to Challenge Eli Lilly and Celgene in Late-Phase Clinical Trials
Marketwire - Wed Feb 19, 8:03AM CST
Nuvilex, Inc. (OTCQB: NVLX) is a small biotech firm in Silver Spring, Maryland, that hopes to soon be mentioned with much larger biotechnology and pharmaceutical companies like Eli Lilly and Celgene. If the company's pancreatic cancer treatment that combines the proprietary cellulose-based live-cell encapsulation technology known as Cell-in-a-Box(TM) with the anti-cancer drug ifosfamide can produce the same or better data in its upcoming late-phase clinical trials in advanced, inoperable pancreatic cancer than were seen with this same combination in two earlier independent Phase II trials, then not only will it be mentioned with those larger companies, Nuvilex's treatment will likely be the new "gold standard" for the disease.
The Zacks Analyst Blog Highlights:Tesla Motors, Celgene, Actelion, Alexion Pharmaceuticals and Medivation
PR Newswire - Tue Feb 18, 8:30AM CST
Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include the Tesla Motors, Inc. (Nasdaq:TSLA-Free Report), Celgene Corporation (Nasdaq:CELG-Free Report), Actelion Ltd. (OTC:ALIOF-Free Report), Alexion Pharmaceuticals, Inc. (Nasdaq:ALXN-Free Report) and Medivation Inc. (Nasdaq:MDVN-Free Report).
Research and Markets: Nanotechnology Drug Delivery Market in the US 2012-2016 with Celgene Corp., Novartis AG and SkyePharma plc. Dominating
Business Wire - Wed Mar 12, 12:42PM CDT
Research and Markets (http://www.researchandmarkets.com/research/r75h94/nanotechnology) has announced the addition of the "Nanotechnology Drug Delivery Market in the US 2012-2016" report to their offering.
Nanotechnology Drug Delivery Market in the US 2012-2016 with Celgene Corp., Novartis AG and SkyePharma plc. Dominating
M2 - Wed Mar 12, 11:14AM CDT
Research and Markets (http://www.researchandmarkets.com/research/3r7bw6/nanotechnology) has announced the addition of the "Nanotechnology Drug Delivery Market in the US 2012-2016" report to their offering. The analysts forecast the Nanotechnology Drug Delivery market in the US to grow at a CAGR of 84.79 percent over the period 2012-2016. One of the key factors contributing to this market growth is the low R and D cost. The Nanotechnology Drug Delivery market in the US has also been witnessing the trend of emergence of personalized medicines. However, the increasing safety concerns could pose a challenge to the growth of this market. Key vendors dominating this space include Alkermes plc., Celgene Corp., Novartis AG and SkyePharma plc. Other vendors mentioned in the report are Merck and Co. Inc., Pfizer Inc., AlphaRx Inc., Amgen, Inc., Angiotech Pharmaceuticals, Inc., Biophan Technologies, Inc., Calando Pharmaceuticals, Inc., Cephalon, Inc., Cerulean Pharma, Inc, Copernicus Therapeutics, Inc., CritiTech, Inc., CytImmune Sciences, Inc., Elan Corporation, plc, Debiotech SA, F. Hoffmann-La Roche Ltd, Nano Interface Technology, Inc, Spherics, Inc., Spectrum Pharmaceuticals, Inc., SoluBest Ltd., Sigma-Tau Pharmaceuticals, Inc., PharmaNova Inc. Particle Sciences, Inc., Novavax, Inc., Nanotherapeutics, Inc., NanoSight Ltd., NanoCarrier Co. Ltd., NanoBioMagnetics, Inc., Nano Interface Technology, Inc, Merck Sharp and Dohme Corp., Kuecept Ltd., Izon Science Ltd. Commenting on the report, an analyst from the Healthcare team said: 'Over the years, the research activities in healthcare have changed significantly. There has been a paradigm shift away from blockbusters drugs to a more personalized medicine approach. The focus is being placed increasingly on formulating drugs based on the individual's unique genome and immune response. Personalized medicines have gained significant popularity because they enable the medical profession to provide customized treatment to patients. A customized treatment is based on the genetic as well as medical profile of a patient. Increasing knowledge about the molecular causes of diseases is increasing the demand for more targeted and effective nanotechnology-enabled drug delivery therapies.' For more information visit http://www.researchandmarkets.com/research/3r...technology About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
2014 Nanotechnology in Drug Delivery Global Strategic Business Report - Liposomes Leading the Way
M2 - Tue Mar 11, 6:28AM CDT
Research and Markets (http://www.researchandmarkets.com/research/6brvm7/nanotechnology_in) has announced the addition of the "Nanotechnology in Drug Delivery - Global Strategic Business Report" report to their offering. This report analyzes the worldwide markets for Nanotechnology in Drug Delivery in US$ Million. The Global Market is further analyzed by the following Drug Delivery Technologies: Nanocrystals, and Nanocarriers. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, Latin America, and Rest of World. Annual estimates and forecasts are provided for the period 2009 through 2018. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based on public domain information including company URLs. Key Topics Covered I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS II. EXECUTIVE SUMMARY 1. OUTLOOK 2. INDUSTRY OVERVIEW 3. TRENDS & ISSUES - Tough Market Conditions Drive Interest in Nanotechnology-Based Drug Delivery - Unmet Needs to Surge Interest in Nanotechnology- based Drug Delivery - Narrowing Drug Pipelines and Threat from Generics Raise Interest in Nanotechnology - Size - A Critical Factor in Improving Targeting Capability - Shape of Drug Carriers More Important than Size - A New Revelation - Existing Nanotechnology Drugs are Simple - Creation of New Therapeutics - The Next Avenue for Nanotechnology - Consumer Pull to Benefit Nanotechnology Based Drugs - Oral Therapies to Revel from Advances in Nanotechnology - Increasing Funding for Nanotechnology Based Therapeutics Development - Convergence of Enabling Technologies - A New Phase in Drug Delivery - Cloudy Future Threatens Advanced Drug Delivery Technologies with Premature Demise - Increasing Environmental and Health Concerns - A Critical Challenge to Technological Advancement - Limited Success and Scaling Up Issues Pose a Major Hurdle to Further Advancement - Financial and Economic Challenges Hurt Developmental Efforts - Higher Concentration of Research in Academia limits Commercialization - Collaborations Assume Importance - Nano Drug Delivery to Drive Tremendous Industry Activity Going Ahead - Challenges to Leveraging Technological Advancements for Boosting Drug Delivery Efficiency - Nanomedicine Regulation - the Approach and the Issues Associated - Regulations in Nanotechnology - Still Significant Room Exists for Improvement 4. NANOTECHNOLOGY-BASED DRUG DELIVERY APPLICATIONS 5. PRODUCT OVERVIEW 6. RECENT INDUSTRY ACTIVITY 7. FOCUS ON SELECT PLAYERS 8. GLOBAL MARKET PERSPECTIVE III. MARKET 1. THE UNITED STATES 2. CANADA 3. JAPAN 4. EUROPE 5. ASIA-PACIFIC 6. LATIN AMERICA 7. REST OF WORLD IV. COMPETITIVE LANDSCAPE Reasons To Buy The report profiles 60 companies including many key and niche players such as: - Access Pharmaceuticals - Alkermes - Aquanova - Camurus - Capsulution - Celgene - Ceramisphere - Crititech - EnColl - Enzon Pharmaceuticals - Flamel Technologies - Lena Nanoceutics - NanoBio? - NanoCarrier - Nano Interface Technology - pSivida For more information visit http://www.researchandmarkets.com/research/6b...hnology_in About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Global Orphan Drugs Market 2014-2018: Novartis, F. Hoffmann-La Roche, Celgene, Pfizer & Sanofi Dominate the Market
M2 - Fri Mar 07, 8:29AM CST
Research and Markets (http://www.researchandmarkets.com/research/73j57p/global_orphan) has announced the addition of the "Global Orphan Drugs Market 2014-2018" report to their offering. The Global Orphan Drugs market to grow at a CAGR of 5.67 percent over the period 2013-2018. The report states that one of the main challenges is the high cost of drug development. The rise in the cost of drug development often tends to discourage pharmaceutical innovators from developing orphan drugs. There has been increase in awareness about the potential benefits of orphan drugs among patients, surgeons, and hospitals. Public awareness about the use of orphan drugs is rapidly growing as a result of increasing social and public exposure and more advocacy groups and awareness campaigns. For instance, in 2010, the US FDA created the Rare Disease Program within the Office of New Drugs with the specific focus of developing the policies and procedures for the review of new drug applications for orphan drug products and to ensure access to appropriate training for US FDA reviewers. Similarly in 2012, the US FDA hosted the first ever US FDA Rare Disease Patient Advocacy Day to enhance the rare disease patient advocacy community's awareness of the US FDA's roles and responsibilities in the development of products for rare diseases. Thus, with the increasing awareness of orphan drugs, the market is expected to witness positive growth in the near future. According to the report, one of the main drivers in this market is the shorter development timelines. The clinical trials of orphan drugs for rare diseases involve fewer patients, which contributes to a shorter development process. The report covers the Americas, and the EMEA and APAC regions; it also covers the Global Orphan Drugs market landscape and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market. Key vendors dominating this space are: - Novartis AG - F. Hoffmann-La Roche Ltd. - Celgene Corp. - Pfizer Inc. - Sanofi S.A. For more information visit http://www.researchandmarkets.com/research/73...bal_orphan
Critical Alerts For Priceline.com, Celgene, CBS, Chipotle Mexican Grill, and AngloGold Ashanti Released By InvestorsObserver
PR Newswire - Thu Mar 06, 8:31AM CST
InvestorsObserver issues critical PriceWatch Alerts for PCLN, CELG, CBS, CMG, and AU.
Concise Analysis of the International Bispecific Antibody Therapeutics Market
M2 - Tue Mar 04, 6:18AM CST
Research and Markets (http://www.researchandmarkets.com/research/c63zqb/bispecific) has announced the addition of the "Concise Analysis of the International Bispecific Antibody Therapeutics Market" report to their offering. Antibody based therapeutics are the fastest growing segment of the drugs and biologics market. There are 30 approved antibody based therapeutics available in the US and European markets since the launch of first anti-CD3 antibody, Orthoclone Okt3, in 1986. A bispecific antibody is a second generation immunotherapy, an upgraded version of monoclonal antibody improved in structure and functionality. The conjugated artificial antibodies are formed by physically putting together two monoclonal antibodies (or parts of) which have different binding specificities. This results in a combination antibody that has simultaneous functional binding affinities to two or three different epitopes. The combination may have additive and sometimes even a synergistic effect in combating a disease. With the EMA approval for Removab in 2009, a great deal of interest has been generated in the bispecific antibody market. The pipeline is rich and diverse, with drugs being developed for both oncological and non-oncological indications. The industry has drugs in phase I and phase II of clinical trials but currently lacks drugs in phase III. The Bispecific Antibody Therapeutics Market, 2013-2023 report extensively studies the current and upcoming market of the bispecific antibodies for therapeutic use. This new class of antibody based therapeutics are likely to help target and combat multifactorial diseases through their potential to bind two antigens simultaneously. Key Topics Covered: 1. EXECUTIVE SUMMARY 2. INTRODUCTION 3. MARKET OVERVIEW AND PIPELINE OF BISPECIFIC ANTIBODIES 4. CURRENT MARKET AND FORECAST 5. TECHNOLOGY PLATFORMS 6. PROFILES OF LEADING COMPANIES 7. SWOT ANALYSIS 8. CONCLUSIONS 9. LIST OF COMPANIES AND ORGANISATIONS 10. TABLES Companies Mentioned: - Abbvie - Ablynx - BMS - Boehringer Ingelheim - Celgene - Chiome Bioscience - Chromacon - Chugai - Covagen - Dow Pharma - Dutalys - EMD Serono - Eli Lilly - Emergent - Epigen Biotech - Fabion Pharmaceuticals - GSK - Imclone Systems - Mitsubishi Tanabe - Molecular Partners AG - Novartis - Novimmune - Numab - OcellO - Oncomed - OtSuka Pharma - Paktis Antibody Services GmbH - Pfizer - Synimmune - Tanabe Research Labs - Trion - UCB-Celltech - X-Body Biosciences - Xencor - Zymeworks - Zymogenetics - Zyngenia For more information visit http://www.researchandmarkets.com/research/c63zqb/bispecific
Concise Analysis of the Future Prospects of Global Personalized Medicine Market
M2 - Tue Mar 04, 5:49AM CST
Research and Markets (http://www.researchandmarkets.com/research/zpctsr/future_prospects) has announced the addition of the "Concise Analysis of the Future Prospects of Global Personalized Medicine Market" report to their offering. Over the years, the Global Personalized Medicine market has been witnessing the emergence of various tools and technologies from the reputed vendors. For instance, AssureRx Health Inc. launched GeneSightRx ADHD in May 2012, a personalized medicine test for the growing number of children and adults diagnosed with ADHD. Moreover, Bristol-Myers Squibb Co. collaborated with MMRF in December 2012 for advanced personalized medicine for multiple Myeloma. Further, Alacris Theranostics GmbH entered into an agreement with GlaxoSmithKline plc in November 2012 to use ModCell system for early stage cancer research. Further, AltheaDx Inc. launched FLT3 Mutation Assay in October 2012. Agendia N.V. launched ColoPrint microarray-based 18-gene expression signature in June 2012 for predicting the risk of distant recurrence for stage II colon cancer patients. The European Medicines Agency approved Zelboraf, manufactured by F. Hoffmann-La Roche Ltd., in December 2011. Key Topics Covered: 1. Executive Summary 2. List of Abbreviations 3. Introduction 4. Market Research Methodology 5. Scope of the Report 6. Market Landscape 7. Geographical Segmentation 8. Key Leading Countries 9. Vendor Landscape 10. Buying Criteria 11. Market Growth Drivers 12. Drivers and their Impact 13. Market Challenges 14. Impact of Drivers and Challenges 15. Market Trends 16. Key Vendor Analysis 17. Other Reports in this Series Companies Mentioned: - Abbott Laboratories - Boehringer Ingelheim GmbH - Bristol-Myers Squibb Co. - Celgene Corp. - Daiichi Sankyo Co. Ltd. - Danaher Corp. - Eli Lilly and Co. - Evotec AG - F. Hoffmann-La Roche Ltd. - GE Healthcare Ltd. - Genelex Corp. - GlaxoSmithKline plc - Hologic Inc. - Johnson & Johnson - Laboratory Corporation of America Holdings - Life Technologies Corp. - Merck KGaA - Mitsubishi Tanabe Pharma Corp. - Myriad Genetics Inc. - Novartis AG - Novartis AG - PerkinElmer Inc. - Pfizer Inc. - Pfizer Inc. - Quest Diagnostics Inc. - Sanofi S.A. - Sanofi S.A. - Siemens Healthcare - Sigma-Aldrich Corp. - Takeda Pharmaceutical Co. Ltd. - Teva Pharmaceutical Industries Ltd. - Thermo Fisher Scientific Inc. - Transgenomic Inc. For more information visit http://www.researchandmarkets.com/research/zp..._prospects
Global Cell Therapy Market & Pipeline Insight Research Report
M2 - Tue Mar 04, 3:02AM CST
Research and Markets (http://www.researchandmarkets.com/research/5kmmgq/global_cell) has announced the addition of the "Global Cell Therapy Market & Pipeline Insight" report to their offering. Research in cell therapy is transforming the future of medicine. As the life of a human being begins as a cell, these cells undergo a highly complex set of events and finally those few stems become capable of self-renewal and differentiation and develop into the specialized cells in the body. Cell therapy research also offers significant potential for restructuring the method of medical practice. Over the past 3-5 years, a more complex therapeutic modality has been is emerging as cell therapies which have been developed to treat diseases which are not amenable to treatment with more classical pharmaceutical or biopharmaceutical products. This market offers the promise of successfully regenerating damaged tissues and organs in the body by replacing the damaged tissue and/or by stimulating the body's own repair mechanisms to heal previously irreparable tissues. With their rising popularity, these therapies are becoming more cost effective and efficient. The global market for cell therapy was valued at close to USD 2.5 Billion in 2012. With continuous advances and developments in this field of medicine, the global cell therapy market is expected to grow at a high rate of 20-22% to reach approximately USD 8 Billion by 2018. Several products and technologies of cell-based therapies are in the R&D pipeline are expected to enter the market during the forecast period, thus resulting in an increased growth rate. It is most likely that the new improved technologies would revolutionize the area of bio-pharma and personalized medicine. Development of sophisticated automation devices for cell expansion and culture process for use in the treatment is one of the emerging trends of ACT market. With the cell-based therapies growing by leaps and bounds, it is expected that the future years would witness significant advancements in technology in the cell therapy market. Increasing incidence of diseases along with lack of adequate effective treatment for these diseases is most likely to drive the cell therapy technology in developed and developing nations. Among the emerging trends of the global market, the most prominent one is the development of sophisticated automation devices for cell expansion and culture process which could be used in the treatment of life threatening diseases. Global Cell Therapy Market & Pipeline Insight Report Highlights & Findings: - Introduction to Cell therapy - Global Cell Therapy Market Overview - Global Cell Therapy Market Dynamics - Cell Therapy Pipeline by Phase, Country & Target Indications - Cell Therapy Drugs in Pipeline: More Than 200 - Highest Number of Drugs in Preclinical Stage: 73 - Number of Drugs in Phase I/II Stage: 35 - Key Market: US - Majority Cell therapies For Cancer Treatment Companies Mentioned - Advanced Cell Technology - Amgen - California Stem Cell - Celgene Corporation - Cytomedix - Fibrocell Science - Genzyme - NeoStem - Novartis - Stemedica Cell Technologies For more information visit http://www.researchandmarkets.com/research/5k...lobal_cell About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Abide Therapeutics Announces Strategic Drug Discovery Collaboration with Celgene Corporation to Advance Treatment Paradigm for Patients with Immune Disorders
PR Newswire - Fri Feb 28, 7:00AM CST
Abide Therapeutics today announced it has entered into a strategic collaboration with Celgene Corporation to discover and develop new drugs in inflammation and immunology. Abide has pioneered innovative technologies to selectively target serine hydrolases, one of the largest enzyme families involved in regulating human physiology.
Epizyme Announces 2013 Operating and Financial Results and Provides 2014 Guidance
PR Newswire - Thu Feb 27, 3:00PM CST
Epizyme, Inc. (NASDAQ: EPZM), a clinical stage biopharmaceutical company creating innovative personalized therapeutics for patients with genetically defined cancers, today announced 2013 operating and financial results and provided 2014 guidance.
Cystic Fibrosis Partnering 2009-2014 Research Report
M2 - Thu Feb 27, 3:45AM CST
Research and Markets (http://www.researchandmarkets.com/research/b4dg6p/cystic_fibrosis) has announced the addition of the "Cystic Fibrosis Partnering 2009-2014" report to their offering. Cystic Fibrosis Partnering 2009-2014 provides understanding and access to the cystic fibrosis partnering deals and agreements entered into by the worlds leading healthcare companies. The report provides an analysis of cystic fibrosis partnering deals. The majority of deals are discovery or development stage whereby the licensee obtains a right or an option right to license the licensors cystic fibrosis technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes. Understanding the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered - contract documents provide this insight where press releases do not. This data driven report contains over 50 links to online copies of actual liver disease deals and contract documents as submitted to the Securities Exchange Commission by companies and their partners, where available. Contract documents provide the answers to numerous questions about a prospective partner's flexibility on a wide range of important issues, many of which will have a significant impact on each party's ability to derive value from the deal. The initial chapters of this report provide an orientation of cystic fibrosis partnering trends. In Cystic Fibrosis Partnering 2009-2014, the available deals are listed by: - Headline value - Upfront payment value - Royalty rate value - Company A-Z - Industry sector - Stage of development at signing - Deal component type - Technology type Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand. Key Topics Covered: Executive Summary Introduction Trends in cystic fibrosis partnering Leading cystic fibrosis deals Dealmaking directory Partnering resource center Appendices Table of figures Companies Mentioned Abbott AstraZeneca Baxter International Celgene CSL Daiichi Sankyo Eisai Endo Pharmaceuticals Forest Laboratories Galderma Hospira Johnson & Johnson Kyowa Hakko Kirin Lundbeck Menarini Novartis Novo Nordisk Otsuka Pfizer Purdue Roche Sanofi Takeda Valeant Warner Chilcott Watson For more information visit http://www.researchandmarkets.com/research/b4...c_fibrosis About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Global Psoriasis Drug Forecast and Market Analysis to 2022 - Sales by region
M2 - Thu Feb 27, 2:55AM CST
Research and Markets (http://www.researchandmarkets.com/research/bkkwwm/pharmapoint) has announced the addition of the "PharmaPoint: Psoriasis - Global Drug Forecast and Market Analysis to 2022" report to their offering. 2012 PsO drug sales to be $5.6 billion across the nine major markets (9MM) covered in this report: US, France, Germany, Italy, Spain, UK, Japan, China, and India. By forecast end in 2022, sales will increase to over $7.62 billion at a Compound Annual Growth Rate (CAGR) of 3.1%, which includes seven pipeline therapies and the launch of biosimilars. This growth will be driven by: - The launch of novel PsO products, such as Eli Lilly's ixekizumab, Amgen's brodalumab, Novartis' secukinumab, Merck's MK-3222, Pfizer's Xeljanz (tofacitinib), Celgene's apremilast, and Biocon's Alzumab (itolizumab) - The uptake of biosimilars for the currently marketed biologics: etanercept, adalimumab, infliximab, and ustekinumab - Increased access to PsO biologics in China and India Despite these drivers, the PsO market will be crowded, yet comprised of diversified therapies. Individual drugs will struggle to gain a foothold as they distinguish themselves from each other. Unmet Needs in Psoriasis While dermatologists agree that the current biologics have revolutionized the PsO landscape, there is a dire need for therapies that can provide long-lasting effects, without side effects or an increased risk of comorbidities. The current pipeline includes at least four novel therapies that have exceptionally high clinical efficacy and good safety profiles, and these include: Novartis' secukinumab, Amgen's brodalumab, Merck's MK-3222, and Eli Lilly's ixekizumab. The dosing schedule for these therapies is quite convenient, as some of them are dosed once monthly and four times a year on average. Interestingly, of the seven pipeline products, three are me-too biologics, each of which targets the cytokine interleukin-17 (IL-17). However, we expect Novartis' inhibitor to be the first of this group to launch in 2014. Key Topics Covered: 1 Tables & Figures 2 Introduction 3 Disease Overview 4 Epidemiology 5 Disease Management 6 Competitive Assessment 7 Opportunity and Unmet Need 8 Pipeline Assessment 9 Current and Future Players 10 Market Outlook 11 Appendix Companies Mentioned - Amgen - AbbVie (Abbott) - Johnson & Johnson - Novartis - Pfizer - Eli Lilly - Merck - LEO Pharma - Celgene For more information visit http://www.researchandmarkets.com/research/bk...harmapoint
Chicago Investment Firm Assumes $27 Million Risk to Help Nuvilex Unseat Celgene and Eli Lilly
Marketwire - Mon Feb 24, 8:04AM CST
Lincoln Park Capital (LPC) purchased 8 million restricted shares of Nuvilex, Inc. (OTCQB: NVLX) in exchange for an initial $2 million out of what can be viewed as a $27 million "pot of money" to advance the company's late-phase pancreatic cancer clinical trials. Notice we said restricted shares, that's right, LPC has put a great deal of its money on the line with a number of built in protections for Nuvilex. But, is this investment really a risk? It appears the Chicago-based firm knows exactly what the future could hold for Nuvilex, and they're comfortable with paying a premium price to become a long-term investor right along with many others who believe in the small biotechnology firm.
US Orphan Drug Market Outlook 2018 Research Report
M2 - Mon Feb 24, 3:25AM CST
Research and Markets (http://www.researchandmarkets.com/research/nhk3cb/us_orphan_drug) has announced the addition of the "US Orphan Drug Market Outlook 2018" report to their offering. In the largest market for orphan drugs, USA, there was a shortage of adequate therapies for treating many rare diseases. These therapies were not developed as companies did not expect these drugs to be highly profitable. Hence there was a lack of interest and thus investment on the part of pharma companies in the USA. Therefore, the FDA introduced incentives for developing such drugs. This step taken by the FDA was successful in creating a thriving market for orphan drugs. It was in the USA first that a special law exclusively for governing orphan drugs was framed in the form of the Orphan Drug Act of 1983. This led to an increase in the popularity of orphan drugs. The FDA also has been continuously increasing its efforts to support this market by providing significant financial and non-financial incentives to the pharmaceutical companies to attract them. This has been one of the major drivers of growth for the US orphan drugs market. The orphan drugs enjoy significant competitive advantages in the market owing to the market exclusivity period after the drug has been authorized. Through this clause, the manufacturer of orphan drugs is given a monopoly status in the market because according to the law, no other company is allowed to market the orphan drugs during the exclusivity period. Additionally, this monopolistic power is further strengthened with the fact that no other alternative health technology exists for many orphan drugs. A scenario where orphan drugs would be denied coverage is highly difficult to visualize. However it is most likely that the payer scrutiny would increase with new products entering the market and budgets contracting in a weakening economic environment. The plans would be based on costs and would also include payer resources, philosophies, and available benefit design options, as all these factors could affect patient access. A deep and clear understanding of the clinical and economic value of the drugs will play an increasingly important role in decision-making. US Orphan Drug Market Outlook 2018 gives a comprehensive insight on following developments related to US orphan drug market: - US Orphan Drug Market Overview - Orphan Drug Designation Criteria - Market Specific Reimbursement Policy & Regulatory Framework - US Orphan Drug Pipeline by Phase, Indication & Originator - Marketed Orphan drug List by Indication & Brand Name - Key Issue to be Resolved - Competitive Landscape Key Topics Covered: Introduction to Orphan Drugs Why Shift from Non-Orphan to Orphan Drugs? US Orphan Drug Market Outlook US Orphan Drug Regulatory Framework US Orphan Drug Pipeline Insight by Phase & Indication Marketed Orphan Drugs in US: Brand Name & Indication Key Issue to be Resolved Competitive Landscape List of Tables List of Figure Companies Mentioned - Alexion - Biogen Idec - Bristol Myers Squibb - Celgene - Eli Lilly (Genzyme Corporation) - Glaxosmithkline - Merck - Novartis Pharmaceuticals - Pfizer - Rare Disease Therapeutics - Roche (Genentech) - Sanofi For more information visit http://www.researchandmarkets.com/research/nh...rphan_drug About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Move Over Celgene Here Comes Nuvilex and $27 Million to Advance Its Pancreatic Cancer Clinical Trials
Marketwire - Fri Feb 21, 8:00AM CST
Nuvilex, Inc. (OTCQB: NVLX) just became relevant in the biotech industry. The company can now move forward with its clinical trials for the treatment of advanced inoperable pancreatic cancer after Nuvilex landed a $27 million funding deal that could change the sector for years to come. Funding is always the biggest hurdle for any small biotechnology or pharmaceutical firm, and its why larger firms with competing treatments can often sit back without worry of new competition.
Bispecific Antibodies: Clinical Trial Tracker
M2 - Fri Feb 21, 4:31AM CST
Research and Markets (http://www.researchandmarkets.com/research/kmc65d/bispecific) has announced the addition of the "Bispecific Antibodies: Clinical Trial Tracker" report to their offering. Bispecific antibodies (bsAbs) are artificial antibodies created by joining together two monoclonal antibodies (or parts) that target different epitopes. The resulting antibody has binding affinities for two or three different epitopes concurrently. Various technology platforms have been used for bsAbs production over the years. These platforms are based on the concepts of chemical crosslinking, hybrid hybridomas, with the latest being recombinant techniques. Different binding sites can be exploited to produce bispecific systems with different mechanisms, such as the T cell engager system. As of now, only one bsAb, Removab, approved for malignant ascites is available in the market. The focus of the pipeline drugs is on oncology as well as on non-oncological indications such as rheumatoid arthritis and other inflammatory diseases. The primary objective of this report is to capture details on the various clinical and preclinical trials which are currently underway in the field of Antibody Drug Conjugates. A number of such trials which are taking place for a variety of indications across multiple geographies have been identified. The information has also been presented in the form a dashboard to provide a high level quick overview of the ongoing activity in this space. In addition to the clinical trial details, the report also provides the following: Detailed forecasts of the bispecific antibody market over the course of next ten years. Owing to the niche nature of this market, we have presented three scenarios to add robustness to our market forecast. The conservative, base and optimistic scenarios represent three different tracks of industry evolution. Industry SWOT analysis summarising the challenges as well as opportunities in the market for different stakeholders Key Topics Covered: I. Introduction and Pipeline Details Section 1: Market Overview Section 2: Dashboard: Pipeline Analysis Section 3: Molecules in Clinical Development: Trial Details Section 4: Molecules in Preclinical Development: Trial Details Section 5: Inclusion / Exclusion Criteria II Market Forecast, 2013 - 2023 Section 6: Market Forecast: Assumptions Section 7: Market Forecast: Details Section 8: Comparative Forecast Scenarios III. Industry Analysis Section 9: Industry SWOT Analysis List of Figures List of Tables Companies Mentioned - AbbVie - Baliopharm - Celgene - Dutalys - Eddingpharm - Fabion Pharmaceuticals - Ganymed Pharmaceuticals - Ho Research Consortium - ImClone System - Janssen Biotech - Krankenhaus Nordwest - MacroGenics - Nantes University Hospital - OncoMed Pharmaceuticals - Paktis Antibody Services GmbH - Radboud University - Sanofi - Technische Universit?t M?nchen - University Hospital Tuebingen - Xencor - Zymeworks and many more... For more information visit http://www.researchandmarkets.com/research/kmc65d/bispecific About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Worldwide Nanomedicine Market Report 2013-2019: Neurology, Cardiovascular, Anti-inflammatory, Anti-infective & Oncology Applications
M2 - Wed Feb 19, 9:05AM CST
Research and Markets (http://www.researchandmarkets.com/research/4bpxtn/nanomedicine) has announced the addition of the "Nanomedicine Market - Global Industry Analysis, Size, Share,Growth, Trends and Forecast, 2013 - 2019" report to their offering. This report includes market estimations for the nanomedicine market for the forecast period 2013 - 2019. The market size is represented in terms of USD billion and the market estimates and forecasts are calculated, considering 2012 as the base year. Moreover, market trends and recent developments have been kept into account while forecasting market growth and revenue for the period 2013 - 2019. The overall nanomedicine market is segmented on the basis of application and geography and the market estimations for each of these segments, in terms of USD billion, is provided in this report. The nanomedicine market, by applications is segmented into neurological, cardiovascular, oncology, anti-inflammatory, anti-infective and other markets. The nanomedicine market is also estimated and analyzed on the basis of geographic regions such as North America, Europe, Asia-Pacific and rest of the world. The global trends such as drivers, restraints and opportunities of the global nanomedicine market is detailed in the market overview chapter of this report., with a view on impact of these factors on market growth along the course of the forecast period. The chapter on competitive landscape consists of heat map analysis of the key players operating in the global nanomedicine market. Some of the key players of this market include GE Healthcare, Mallinckrodt plc, Nanosphere Inc., Pfizer Inc., Merck & Co Inc., Celgene Corporation, CombiMatrix Corporation, Abbott Laboratories and others. The role of these market players in the global nanomedicine market is analyzed by profiling them on the basis of attributes such as company overview, financial overview, product portfolio, business strategies, and recent developments. The global nanomedicine market is categorized into the following segments: - Neurology - Cardiovascular - Anti-Inflammatory - Anti-Infectives - Oncology - Others Key Topics Covered: Chapter 1 Preface Chapter 2 Executive Summary Chapter 3 Global Nanomedicine Market Overview Chapter 4 Global Nanomedicine Market, by Applications Chapter 5 Global Nanomedicine Market, by Geography Chapter 6 Recommendations Chapter 7 Company Profiles - Abbott Laboratories - Celgene Corporation - CombiMatrix Corporation - GE Healthcare - Johnson & Johnson - Mallinckrodt plc. - Merck & Company Inc. - Nanosphere, Inc. - Pfizer Inc. - Sigma-Tau Pharmaceuticals Inc. - Teva Pharmaceutical Industries Ltd. - UCB SA For more information visit http://www.researchandmarkets.com/research/4b...nomedicine
Cogent Reports(TM): Genentech Regains Its Dominance in Image Among Oncologists
Business Wire - Wed Feb 19, 9:00AM CST
Genentech has made notable gains as the top oncology franchise among oncologists over the past year, as evidenced by significantly higher scores across all key performance drivers, especially research and development (R&D) and developing beneficial products. Celgene and Amgen also show gains among oncologists, while Novartis remains the leader among hematologists. This and other findings can be found in the Cogent Reports Oncology Image Study from Market Strategies International.
Nuvilex's Pancreatic Cancer Treatment Readies to Challenge Eli Lilly and Celgene in Late-Phase Clinical Trials
Marketwire - Wed Feb 19, 8:03AM CST
Nuvilex, Inc. (OTCQB: NVLX) is a small biotech firm in Silver Spring, Maryland, that hopes to soon be mentioned with much larger biotechnology and pharmaceutical companies like Eli Lilly and Celgene. If the company's pancreatic cancer treatment that combines the proprietary cellulose-based live-cell encapsulation technology known as Cell-in-a-Box(TM) with the anti-cancer drug ifosfamide can produce the same or better data in its upcoming late-phase clinical trials in advanced, inoperable pancreatic cancer than were seen with this same combination in two earlier independent Phase II trials, then not only will it be mentioned with those larger companies, Nuvilex's treatment will likely be the new "gold standard" for the disease.
The Zacks Analyst Blog Highlights:Tesla Motors, Celgene, Actelion, Alexion Pharmaceuticals and Medivation
PR Newswire - Tue Feb 18, 8:30AM CST
Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include the Tesla Motors, Inc. (Nasdaq:TSLA-Free Report), Celgene Corporation (Nasdaq:CELG-Free Report), Actelion Ltd. (OTC:ALIOF-Free Report), Alexion Pharmaceuticals, Inc. (Nasdaq:ALXN-Free Report) and Medivation Inc. (Nasdaq:MDVN-Free Report).
(0)
(0)Celgene Corp. (CELG.RT) Stock Research Links
Scroll down for more posts ▼